Abstract
ContextEconomic evaluations are far less frequently reported for medical devices than for drugs. In addition, little is known about the quality of existing economic evaluations, particularly for innovative devices, such as those used in vertebroplasty and kyphoplasty.ObjectiveTo assess the level of evidence provided by the available economic evaluations for vertebroplasty and kyphoplasty.Data SourcesA systematic review of articles in English or French listed in the MEDLINE, PASCAL, COCHRANE and National Health Service Economic Evaluation databases, with limits on publication date (up to the date of the review, March 2014).Study SelectionWe included only economic evaluations of vertebroplasty or kyphoplasty. Editorial and methodological articles were excluded.Data ExtractionData were extracted from articles by two authors working independently and using two analysis grids to measure the quality of economic evaluations.Data SynthesisTwenty-one studies met our inclusion criteria. All were published between 2008 and 2014. Eighteen (86%) were full economic evaluations. Cost-effectiveness analysis (CEA) was the most frequent type of economic evaluation, and was present in 11 (52%) studies. Only three CEAs complied fully with the British Medical Journal checklist. The quality of the data sources used in the 21 studies was high, but the CEAs conforming to methodological guidelines did not use high-quality data sources for all components of the analysis.ConclusionsThis systematic review shows that the level of evidence in economic evaluations of vertebroplasty and kyphoplasty is low, despite the recent publication of a large number of studies. This finding highlights the challenges to be faced to improve the quality of economic evaluations of medical devices.
Highlights
Health technology assessment (HTA) is increasingly used to support healthcare allocation decisions in most health systems [1]
This systematic review shows that the level of evidence in economic evaluations of vertebroplasty and kyphoplasty is low, despite the recent publication of a large number of studies
This finding highlights the challenges to be faced to improve the quality of economic evaluations of medical devices
Summary
Health technology assessment (HTA) is increasingly used to support healthcare allocation decisions in most health systems [1]. The methods currently used for economic evaluations of health products were initially developed with drugs in mind and are often unsuitable for medical devices [3]. Medical devices have wider economic implications that must be assessed, such as an impact on organization or a need for training. Device-operator interactions are very strong and can have a significant impact on the extent to which clinical results can be generalized. For all these reasons, large randomized controlled trials (RCTs) providing valid and unbiased estimates of efficacy are difficult to achieve for medical devices
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
